glp-1 drugs and lupus The anti-inflammatory immunological properties of Receptor Agonists Can GLP-1 Medications Be Considered
Description
The available studies differ in drug type, dose, indication, timing of exposure, comparator structure, and baseline maternal metabolic risk, and the number of exposed pregnancies remains insufficient to exclude uncommon but clinically important harms (132, 133)
As GLP-1RAs become more commonly used, clinicians need to monitor for AV dermatological side effects while planning suitable treatment approaches for patients who develop this condition
A doctor who understands eating disorder history should be part of the prescribing team
For example, the 2018 European Association for the Study of Diabetes (EASD) and American Diabetes Association consensus guidelines recommend a sodiumglucose cotransporter2 (SGLT2) inhibitor or a GLP1 RA with proven cardiovascular benefits for patients with clinical cardiovascular disease
